Phaseline

Companies › Shanghai RAAS Blood Products

Shanghai RAAS Blood Products: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 2, 1 Phase 1; Hematology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SR604
Von Willebrand factor (VWF) mimetic or functional VWF replacement
–Phase 2Von Willebrand Disease (VWD); Hemophilia ADec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07644832SR604Phase 1Hemophilia AHematologyDec 2026
NCT07640893SR604Phase 2Von Willebrand Disease (VWD)HematologyDec 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

S-INFINITY Pharmaceuticals Prothya Biosolutions Imara Bioverativ, a Sanofi company Hangzhou Gensciences Biopharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.